NCT05814536 - IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2023

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2024

Conditions

Cholangiocarcinoma With IDH1 MutationSolid Tumors With IDH1 Mutation

Interventions

DRUG

AB-218 capsule

Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.

Trial Locations (14)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

Unknown

Beijing Jishuitan Hospital, Beijing

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

Sun Yat-sen University Cancer Center, Guangzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

The fourth hospital of Hebei medical university, Shijiazhuang

Henan Cancer Hospital, Zhengzhou

Liaoning Cancer Hospital, Shenyang

Shandong Cancer Hospital, Jinan

Affiliated Hospital of Qingdao University, Qingdao

Shanghai Sixth People's Hospital, Shanghai

The Third Affiliated Hospital of the PLA naval medical university, Shanghai

Shulan (Hangzhou) Hospital, Hangzhou

Jinan Central Hospital, Jinan